ClinicalTrials.gg
CompletedNCT02034591Updated Jun 23, 2016Results posted

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

A Phase 1 interventional study of Apixaban and Boost Plus in Healthy Subjects, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-23.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to assess the bioavailability of Apixaban oral solution administered through an Nasogastric Tube (NGT) in the presence of Boost® Plus and Apixaban administered as crushed tablet through a nasogastric tube relative to Apixaban solution administered orally in healthy subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects as determined by no deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • Any history or evidence of abnormal bleeding or coagulation disorders, intracranial hemorrhage, or abnormal bleeding (including heavy menstrual bleeding that has resulted in anemia within the past 1 year) or coagulation disorders in a first degree relative
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Arm A-Apixaban

    Solution Apixaban 5 mg ( 0.4 mg/ml oral solution x 12.5 ml) through mouth or oral syringe

    Drug: Apixaban

  • Experimental
    Arm B-Apixaban

    Oral Solution Apixaban 5 mg single dose (0.4 mg/mL oral solution x 12.5 mL) after 180 mL of Boost Plus®, followed by 60 mL of Boost Plus® via same NGT

    Drug: Apixaban · Dietary Supplement: Boost Plus

  • Experimental
    Arm C-Apixaban

    Single dose crushed Apixaban tablet 5 mg (5 mg tablet crushed and suspended in 60 mL Dextrose 5% in water (D5W)) through NGT

    Drug: Apixaban

Interventions

  • Also known as: BMS-562247

  • Dietary supplementBoost Plus
06

What researchers measure

Primary outcomes

  1. Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban

    Maximum observed plasma concentration (Cmax) is measured in nanograms per milliliter (ng/mL)

    Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention

  2. Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban

    AUC(INF) is measured in nanogram hours per milliliter (ng\*h/mL)

    Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention

  3. Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban

    AUC(0-T) is measured in nanogram hours per milliliter (ng\*h/mL)

    Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention

Secondary outcomes

  1. Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban

    Maximum observed plasma concentration (Cmax) is measured in nanograms per milliliter (ng/mL)

    Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention

  2. Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban

    AUC(INF) is measured in nanogram hours per milliliter (ng\*h/mL)

    Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention

  3. Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban

    AUC(0-T) is measured in nanogram hours per milliliter (ng\*h/mL)

    Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention

  4. Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths or Discontinuation of Study Drug Due to AEs

    AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v15.1) and graded using the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0

    Time frame: Day 1 to 30 days after last dose of study drug

  5. Number of Participants With Marked Laboratory Abnormalities

    Marked laboratory abnormalities were defined as laboratory assessments meeting the following investigator-specified criteria: Leukocytes \>1.2\* upper limits of normal (ULN) , Basophils \>3%, Eosinophils \>1.5\*ULN, Blood Urine \>=2, Red Blood Cell (RBC) Urine \>=2, White Blood Cell (WBC) Urine \>=2

    Time frame: Day 1 to 30 days after last dose of study drug

07

Results

Posted Jun 23, 2016

Participant flow

Participant flow — Overall Study
MilestoneTreatment A, Then Treatment B, Then Treatment CTreatment A, Then Treatment C, Then Treatment BTreatment B, Then Treatment A, Then Treatment CTreatment B, Then Treatment C, Then Treatment ATreatment C, Then Treatment A, Then Treatment BTreatment C, Then Treatment B, Then Treatment A
Started434343
Completed434333
Not completed000010
Withdrew: Withdrawal by subject000010

Outcome measures

PrimaryAdjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban

Maximum observed plasma concentration (Cmax) is measured in nanograms per milliliter (ng/mL)

Time frame:
Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention
Reported as:
Geometric mean · ng/mL
Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban
ng/mLTreatment ATreatment B
Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban179.116 (164.855 to 194.611)122.145 (112.011 to 133.196)
Statistical analysis
  • Treatment A vs Treatment B · Ratio of adjusted geometric means: 0.682 · 90% CI 0.621 to 0.748
PrimaryAdjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban

AUC(INF) is measured in nanogram hours per milliliter (ng\*h/mL)

Time frame:
Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban
ng*h/mLTreatment ATreatment B
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban1397.666 (1330.658 to 1468.049)1136.380 (1065.716 to 1211.729)
Statistical analysis
  • Treatment A vs Treatment B · Ratio of adjusted geometric means: 0.813 · 90% CI 0.766 to 0.863
PrimaryAdjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban

AUC(0-T) is measured in nanogram hours per milliliter (ng\*h/mL)

Time frame:
Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban
ng*h/mLTreatment ATreatment B
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban1372.836 (1306.240 to 1442.828)1112.493 (1041.751 to 1188.038)
Statistical analysis
  • Treatment A vs Treatment B · Ratio of adjusted geometric means: 0.810 · 90% CI 0.764 to 0.860
SecondaryAdjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban

Maximum observed plasma concentration (Cmax) is measured in nanograms per milliliter (ng/mL)

Time frame:
Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention
Reported as:
Geometric mean · ng/mL
Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban
ng/mLTreatment ATreatment C
Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban179.116 (164.855 to 194.611)158.371 (145.849 to 171.968)
Statistical analysis
  • Treatment A vs Treatment C · Ratio of adjusted geometric means: 0.884 · 90% CI 0.830 to 0.942
SecondaryAdjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban

AUC(INF) is measured in nanogram hours per milliliter (ng\*h/mL)

Time frame:
Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban
ng*h/mLTreatment ATreatment C
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban1397.666 (1330.658 to 1468.049)1327.248 (1246.871 to 1412.806)
Statistical analysis
  • Treatment A vs Treatment C · Ratio of adjusted geometric means: 0.950 · 90% CI 0.905 to 0.997
SecondaryAdjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban

AUC(0-T) is measured in nanogram hours per milliliter (ng\*h/mL)

Time frame:
Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose for each intervention
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban
ng*h/mLTreatment ATreatment C
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban1372.836 (1306.240 to 1442.828)1300.728 (1220.374 to 1386.374)
Statistical analysis
  • Treatment A vs Treatment C · Ratio of adjusted geometric means: 0.947 · 90% CI 0.903 to 0.994
SecondaryNumber of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths or Discontinuation of Study Drug Due to AEs

AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v15.1) and graded using the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0

Time frame:
Day 1 to 30 days after last dose of study drug
Reported as:
Number · participants
Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths or Discontinuation of Study Drug Due to AEs
participantsTreatment ATreatment BTreatment C
SAE001
Treatment-Related AE011
Deaths000
Treatment-Related Deaths000
Discontinuation of Study Drug Due to AEs000
SecondaryNumber of Participants With Marked Laboratory Abnormalities

Marked laboratory abnormalities were defined as laboratory assessments meeting the following investigator-specified criteria: Leukocytes \>1.2\* upper limits of normal (ULN) , Basophils \>3%, Eosinophils \>1.5\*ULN, Blood Urine \>=2, Red Blood Cell (RBC) Urine \>=2, White Blood Cell (WBC) Urine \>=2

Time frame:
Day 1 to 30 days after last dose of study drug
Reported as:
Number · participants
Number of Participants With Marked Laboratory Abnormalities
participantsTreatment ATreatment BTreatment C
Leukocytes010
Basophils100
Eosinophils010
Blood, Urine110
RBC, Urine021
WBC, Urine021

Adverse events

Collected over Day 1 to 30 days after last dose of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A—0/20 (0%)6/20 (30%)
Treatment B—0/20 (0%)3/20 (15%)
Treatment C—1/21 (4.8%)1/21 (4.8%)
Most frequent serious events
Most frequent serious events
EventTreatment ATreatment BTreatment C
GastritisGastrointestinal disorders0/200/201/21
Most frequent other events
Most frequent other events
EventTreatment ATreatment BTreatment C
HaematomaVascular disorders0/201/200/21
PyuriaRenal and urinary disorders1/200/200/21
Pain in extremityMusculoskeletal and connective tissue disorders1/200/200/21
HeadacheNervous system disorders1/201/201/21
Vision blurredEye disorders1/200/200/21
Rash macularSkin and subcutaneous tissue disorders1/200/200/21
EpistaxisRespiratory, thoracic and mediastinal disorders1/200/200/21
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/201/200/21
Rash papularSkin and subcutaneous tissue disorders0/201/200/21

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)All Treatment Groups
Mean36.7 (22 to 45)
Sex: Female, Male
Sex: Female, Male(Participants)All Treatment Groups
Female8
Male13
08

Study locations

1 site
  • Healthcare Discoveries, LLC D/B/A Icon Development Solutions
    San Antonio, Texas 78209, United States
09

References and documents

Publications

  • Song Y, Wang X, Perlstein I, Wang J, Badawy S, Frost C, LaCreta F. Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. Clin Ther. 2015 Aug;37(8):1703-12. doi: 10.1016/j.clinthera.2015.05.497. Epub 2015 Jul 15. PubMed 26188837 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2014
First posted
Jan 13, 2014
Start
Oct 2011
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
Jun 23, 2016
Last update
Jun 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02034591
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jan 13, 2014
Start date
Oct 2011
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Jun 23, 2016
Last update
Jun 23, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion